These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2745245)

  • 1. Multiple intravenous dose pharmacokinetic study of carumonam in healthy subjects.
    Patel IH; Soni PP; Portmann R; Suter K; Banken L; Weidekamm E
    J Antimicrob Chemother; 1989 Jan; 23(1):107-11. PubMed ID: 2745245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens.
    Bérubé D; Vallée F; Panneton AC; Bergeron MG; LeBel M
    Antimicrob Agents Chemother; 1988 Mar; 32(3):354-7. PubMed ID: 3364953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of carumonam in patients with renal insufficiency.
    Horber F; Egger HJ; Weidekamm E; Dubach UC; Frey FJ; Probst PJ; Stoeckel K
    Antimicrob Agents Chemother; 1986 Jan; 29(1):116-21. PubMed ID: 3729324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Duffull SB; Landersdorfer CB; Kinzig M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):130-41. PubMed ID: 19748423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS; Summers KK; Hardin TC
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of carumonam (AMA-1080) in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K; Suzuki H; Saruta T; Deguchi N; Fugono T
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1048-52. PubMed ID: 1929242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration of monobactam antibiotics (aztreonam, carumonam) into human prostatic tissue.
    Whitby M; Hempenstall J; Gilpin C; Weir L; Nimmo G
    Chemotherapy; 1989; 35(1):7-11. PubMed ID: 2721291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tissue penetration of carumonam, a new synthetic monobactam.
    McNulty CA; Garden GM; Ashby J; Wise R
    Antimicrob Agents Chemother; 1985 Sep; 28(3):425-7. PubMed ID: 4073864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
    Xu H; Zhou W; Zhou D; Li J; Al-Huniti N
    J Clin Pharmacol; 2017 Mar; 57(3):336-344. PubMed ID: 27530649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of aztreonam.
    Mattie H
    Clin Pharmacokinet; 1988 Mar; 14(3):148-55. PubMed ID: 3286083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys.
    Kita Y; Fugono T; Imada A
    Antimicrob Agents Chemother; 1986 Jan; 29(1):127-34. PubMed ID: 3729325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of aztreonam. An update.
    Mattie H
    Clin Pharmacokinet; 1994 Feb; 26(2):99-106. PubMed ID: 8162661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and dose recommendations of carumonam in renal failure.
    Koeppe P; Höffler D; Strobel K
    Arzneimittelforschung; 1987 Jan; 37(1):65-9. PubMed ID: 3566860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.
    Wong SL; Barriere SL; Kitt MM; Goldberg MR
    J Antimicrob Chemother; 2008 Oct; 62(4):780-3. PubMed ID: 18586659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.
    Vinks AA; van Rossem RN; Mathôt RA; Heijerman HG; Mouton JW
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3049-55. PubMed ID: 17576827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.
    Farinotti R; Trouvin JH; Bocquet V; Vermerie N; Carbon C
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1590-2. PubMed ID: 3190187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of fluconazole in loggerhead sea turtles (Caretta caretta) after single intravenous and subcutaneous injections, and multiple subcutaneous injections.
    Mallo KM; Harms CA; Lewbart GA; Papich MG
    J Zoo Wildl Med; 2002 Mar; 33(1):29-35. PubMed ID: 12216790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.